Curis, Inc. (CRIS) Receives Conditional Approval Recommendation for Erivedge from CHMP
Oncology-focused company Curis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional approval of Erivedge (vismodegib) for treating adult patients with symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is not appropriate for surgery or radiotherapy. Receiving conditional approval would make Erivedge Europe’s first licensed treatment for patients with advanced basal cell carcinoma, which is a rare form of skin cancer that can be disfiguring, debilitating, and even fatal. “We are extremely pleased that the CHMP has recommended the conditional approval of Erivedge in…
